< Back to the list of products
Suvaxyn M.hyo, emulsion for injection for pigs
Suvaxyn M.hyo is considered for several years as the gold standard for Mycoplasma protection in the Swine industry. Its formulation - with Carbopol adjuvant - gives to this vaccine its key properties of safety and efficacy, allowing flexibility in vaccination schedule for a better convenience for use without compromising efficacy and protection.
Description
Each dose of 2 ml of inactivated vaccine contains:
| Active substances: | |
|---|---|
| Inactivated Mycoplasma hyopneumoniae, strain P-5722-3 | RP* (undiluted) > 1.00 |
| Adjuvants: | |
| Carbopol #941 | 4.00 mg |
| Excipients: | |
| Thiomersal Trace of ampicillin |
0.20 mg |
* Elisa Relative Potency Unit by comparison with a reference vaccine, containing 2 x 109 MHDCE per dose.
MHDCE = Mycoplasma Hyopneumoniae DNA cell equivalents.
Indications
For active immunisation against Mycoplasma hyopneumoniae infection in feeder finishing pigs to reduce the frequency and severity of lung lesions.
The onset of immunity is 1 week following the second dose and duration of immunity is at least 4½ months.
CONTRAINDICATIONS
None
ADVERSE REACTIONS
Occasionally, a slight soft swelling of about 2 cm in diameter may be observed at the site of injection which will disappear within a few days.
TARGET SPECIES
Feeder finishing pigs from one to ten weeks of age.
DOSAGE, ROUTE AND METHOD OF ADMINISTRATION
One dose of 2 ml should be administered by intramuscular injection.
A course of two injections two weeks apart is recommended from one to ten weeks of age.
ADVICE ON CORRECT ADMINISTRATION
Shake well before use.
Warm vaccine to body temperature prior to administration.
The second injection should be administered at least three weeks before the expected field challenge occurs.
When administering product from a multi-dose container, use of a multi-dosing automatic syringe is recommended.
Minimum age at first inoculation - one week.
WITHDRAWAL PERIOD
Zero days
SHELF LIFE
Shelf life of the veterinary medicinal product as packaged for sale:
National label conditions must be observed by country.
Shelf life after opening the immediate packaging: use vaccine immediately.
SPECIAL STORAGE PRECAUTIONS
Store and transport refrigerated (2°C - 8°C).
Do not freeze.
Protect from light.
SPECIAL WARNINGS
Vaccinate only healthy animals.
Do not use in pregnant or lactating animals.
Do not administer within 14 days of other vaccinations, as compatibility has not been investigated.
Animals that have received immunosuppressive drugs (e.g. glucocorticoids) should not be vaccinated until an interval of at least 4 weeks has elapsed.
Avoid stress in the animals around time of vaccination.
It is advisable to vaccinate all animals in a herd in order to minimise the spread of infection.
Aseptic precautions should be observed.
Use entire contents when first opened.
Syringes should not have been sterilised chemically or be above ambient temperature.
Use only sterile needles and syringes for administration.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of self-injection seek medical advice immediately and show package leaflet or label to the physician.
Any unused product and waste material should be disposed of in accordance with national requirements.
Prior to first time use on a farm, it is strongly recommended that the advice of a veterinary practitioner is sought.
OTHER INFORMATION
ATC code: Q109AB13
Vaccine should be used only as a tool for disease control together with environmental management
and medication practices designed to minimise the incidence of disease caused by Mycoplasma Hyopneumoniae.
In any animal population there will be a small number of individuals which fail to respond fully to vaccination.
Successful vaccination depends upon correct storage and administration of the vaccine and the animal's
ability to respond. Immune competence can be influenced by genetic factors, intercurrent infection, age, nutritional status, concurrent drug therapy, stress etc.
Immunocompetence in the pig increases with age. Age at vaccination should be determined by consideration
of the timing of field challenge.
For example, earlier vaccination is recommended where early challenge is expected.
Evidence has been obtained from field trials that the vaccine has a protective effect up until
slaughter at 30 weeks of age, when piglets in infected herds are vaccinated as recommended.
Selection of herds where vaccination use is
appropriate and continued monitoring should be carried out by the supervising veterinary surgeon.
Nature and composition of immediate packaging and presentations
Cardboard box containing 1 polyethylene bag with: 50 doses (105 ml) of vaccine.
Cardboard box containing 1 or 10 polyethylene bottles containing: 125 doses (255 ml) and 50 doses (105 ml) of vaccine.
Closures: Butyl rubber stoppers with aluminium caps.
National label conditions must be observed by country.
